Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma  by Lin, Feng et al.
Current Therapeutic Research
Volume 70, Number 2, April 2009
150 
Accepted for publication  January 27, 2009. doi:10.1016/j.curtheres.2009.04.005
© 2009 Excerpta Medica Inc. All rights reserved. 0011-393X/$ - see front matter
Relationship of Serum Methotrexate Concentration in 
High-Dose Methotrexate Chemotherapy to Prognosis 
and Tolerability: A Prospective Cohort Study in Chinese 
Adults With Osteosarcoma
Feng Lin, MD; Yue Juan, MD; Shui-Er Zheng, PhD; Zan Shen, PhD; Li-Na Tang, MD; 
Hui Zhao, MD; and Yang Yao, MD
Department of Oncology, Affiliated People’s 6th Hospital, Shanghai Jiaotong University, 
Shanghai, People’s Republic of China
ABSTRACT
Background: Cancer that originates in the bone, termed primary bone cancer, is 
rare. Osteosarcoma (OS) occurs primarily in growing bone tissue and is more preva-
lent in children and adolescents. OS in adults is rare, with 3 to 5 cases per million 
population per year worldwide. There are limited data on treatment-related prognosis 
and adverse reactions in adults reported in the literature. 
Objectives: The aims of this study were to investigate factors that influence 
serum methotrexate (MTX) concentrations used in chemotherapy in Chinese adult 
patients with OS, and to determine the correlations (based on age, sex, and dosage), if 
any, between MTX and prognosis, in terms of disease-free survival (DFS) and overall 
survival (OAS), and tolerability. 
Methods: Adult patients aged ≥30 years with OS received ≥3 courses (2 courses 
before surgery and 3–4 courses postsurgery) of high-dose MTX (6 or 8 g/m2) com-
bined chemotherapy. The regimen consisted of day 1: MTX + folinic acid (herein 
referred to as citrovorum factor rescue); day 8: cisplatin; days 21 to 25: ifosfamide + 
mesna; and day 21: doxorubicin. Serum MTX concentrations were assessed imme-
diately after the end of infusion (baseline) and at 24 and 48 hours using high- 
performance liquid chromatography. Changes in serum MTX concentrations, factors 
that influence serum MTX concentrations, and the relationship between serum MTX 
concentrations and prognosis and tolerability (determined by adverse reactions) were 
analyzed. Patients received a second course of treatment after a 3-week period. 
Results: Ninety patients (58 men, 32 women; age range, 30–67 years) with 
OS were included in the study. A total of 532 courses of combined chemotherapy were 
administered. The serum MTX concentrations ranged widely at baseline (244.31– 
929.68 mol/L, Cmin and Cmax, respectively) and at 24 hours (0.73–28.24 mol/L, respec-
tively), suggesting that the serum MTX concentrations varied significantly between 
different individuals and within the same individual at different time points. The 
serum MTX concentrations in ~23% of cases (122/532) determined at 24 and/or 
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48 hours were numerically higher than the safety values (according to Nirenberg’s 
reference: irreversible damage if MTX concentration was >10 μmol/L and >1 μmol/L 
at 24 and 48 hours, respectively). No correlation was found between high serum MTX 
concentration at baseline and high serum MTX concentration at 24 hours (r = 0.401). 
The prevalences of the 3 most common adverse reactions in these patients were de-
pressed white blood cell count (44.03%), dental ulcer (23.0%), and rash (18.0%). 
However, in the remaining 410 courses in which serum MTX concentrations were 
lower than the safety values, these prevalences were 14.6%, 3.9%, and 2.4%, respec-
tively. Neither age nor sex was significantly associated with MTX Cmax, but dosage 
was (P < 0.05). Patients with a serum MTX Cmax concentration >500 μmol/L at base-
line had a significantly longer DFS rate than those with ≤500 μmol/L (P = 0.040). 
There were no significant between-group differences in the OAS rates. 
Conclusions: In these Chinese patients with OS, serum MTX concentrations 
measured at different time points were varied. The findings suggest that adverse reac-
tions occurred in patients whose serum MTX concentrations at 24 and/or 48 hours 
were higher than the safety values. The dosage appeared to have influenced MTX 
Cmax, while sex and age did not, and the Cmax was significantly related to DFS but not 
OAS. (Curr Ther Res Clin Exp. 2009;70:150–160) © 2009 Excerpta Medica Inc.
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INTRODUCTION
Cancer that originates in the bone, termed primary bone cancer, is rare. Osteosarcoma 
(OS), a malignant primary tumor, is more prevalent in children and adolescents 
(≥75% compared with adults).1 OS in adults is rare, with 3 to 5 cases per million 
population per year worldwide.1 High-dose (HD) combined chemotherapy, first used 
in the 1970s,1 has been associated with a significant increase of 20% to 50% in 5-year 
survival. Because of its utility, HD methotrexate (MTX) (6–8 g/m2), which is 100-fold 
greater than that of routine MTX dose of 30 to 40 mg/m2, + folinic acid (herein re-
ferred to as citrovorum factor rescue [CFR]) in combined chemotherapy for OS has 
been widely used in clinical practice.1 The recommended dose is different between 
adults and adolescents, and the metabolic process of MTX remains unknown.2,3 
The present study sought to investigate factors that influence serum MTX concen-
trations used in chemotherapy in Chinese adult patients with OS, and to determine 
the correlations (based on age, sex, and dosage), if any, between MTX and prognosis, 
in terms of disease-free survival (DFS) and overall survival (OAS), and tolerability. 
PATIENTS AND METHODS
Inclusion Criteria and Clinical Data
Between July 2003 and December 2007, there were 153 new cases of OS diagnosed 
at the Affiliated People’s 6th Hospital, Shanghai, People’s Republic of China. Eligible 
patients met the following inclusion criteria: age ≥30 years; presence of typical radio-
graphic and histologic features of primary, high-grade OS; diagnosis at stage IIB ac-
cording to the Enneking standard4; no history of cancer and no prior cancer treatment; 
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no coexisting disease contraindicating chemotherapy; and no evidence of metastases 
at diagnosis. Before the start of chemotherapy, patients who met the inclusion cri-
teria had to: reach functional capacity of ≥60% according to Karnofsky Performance 
Status5 criteria; have white blood cell (WBC) count ≥4.0 × 109 cells/L; platelet 
count ≥120 × 109 cells/L; and normal hepatic, renal, and cardiac function electrocar-
diography (ECG) test results. 
Chemotherapy Regimens
All patients received ≥3 courses (2 courses before surgery and 3–4 courses post- 
surgery) of HD-MTX (6 or 8 g/m2) combined chemotherapy. The regimen consisted of 
day 1: MTX + CFR; day 8: cisplatin (DDP); days 21 to 25: ifosfamide (IFO) + mesna; 
and day 21: doxorubicin (ADM). 
Serum MTX Concentration Analysis
Approximately 2 mL of venous blood was collected into a glass tube immediately 
after the start of infusion (0 hour; baseline) and at 24 and 48 hours at the end of the 
6-hour IV HD-MTX infusion. The blood was centrifuged at 3500 rpm for 10 minutes 
and stored at 20°C until analysis. Serum MTX concentrations were measured using 
high-performance liquid chromatography fitted with an lC-8A pump (Shimadzu Cor-
poration, Kyoto, Japan). The parameters were set as follows: the chromato bar was a 
150 × 460 mm Chromegabond BAS C18 (Shimadzu Corp.); sodium acetate buffer 
(pH, 3.5); acetonitrile (89:11 [volume ratio]); flow rate (1.5 mL/min); and mobile 
phase (0.15 mol/L). The mobile phase was ultrafiltrated and degassed by ultrasound. 
The column temperature was 35°C, the ultraviolet detection wavelength was 303 nm, 
and the sample particle size was 10 μL. Detailed methods appear elsewhere in the 
literature.6 The safety values7 of serum drug concentration were ≤10 μmol/L and 
≤1 μmol/L at 24 and 48 hours, respectively.
Chemotherapy Regimen and Observation of Adverse Reactions
A modified Bacci’s8 adjuvant and neoadjuvant chemotherapy regimen (referred to 
as IOR [Istituto Ortopedico Rizzoli]/OS-N5) was used in the present study. A panel 
of senior clinical oncologists determined the dose of MTX administration. On 
day 1, CFR was administered 12 hours after MTX administration (MTX 6 or 8 g/m2 
[IV infusion over 6 hours]; CF 15 mg [administered intravenously q3h × 8]; 
and CF 12 mg [administered intramuscularly q6h × 6]). Patients with lower 
(<100 mL/min) glomerular filtration rate (n = 35) received the lower MTX dose (6 g/m2). 
The frequency of CFR was determined by serum MTX concentration (eg, if the 
MTX concentration increased 2-fold, the CFR was doubled). On day 8, IV DDP 80 to 
100 mg/m2 was administered. On day 21, a 15-minute ADM 60 mg/m2 IV infusion was 
administered. Additionally, on days 21 through 25, IFO 2.0 g/m2 IV was administered 
and mesna 400 to 600 mg was intravenously administered at 0, 4, and 8 hours after IFO 
administration. After a 3-week period, a second course of treatment was started. 
During HD-MTX therapy, patients were advised on sufficient water intake, basic elec-
trolyte (potassium, sodium, magnesium, calcium, and chlorine) balance, kidney protec-
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tion, and bladder control. Prior to the initiation of chemotherapy, patients underwent 
routine blood and urinary tests for hepatic and renal function, as well as ECG. These labo-
ratory values and system functions were also monitored daily for 3 consecutive days while 
patients were undergoing chemotherapy. Adverse reactions were assessed according to the 
World Health Organization9 guidelines for measurement during chemotherapy. Serum 
MTX concentrations outside of safety values,7 defined as >10 μmol/L at 24 hours or 
>1 μmol/L at 48 hours, indicated greater susceptibility to adverse reactions. 
To examine the relationship between Cmax and DFS, patients were divided into 
2 groups (those with MTX Cmax ≤500 μmol/L and those with MTX Cmax >500 μmol/L).
Follow-Up
Patients underwent a follow-up appointment 2 to 3 weeks after chemotherapy was 
discontinued. By the end of June 2008, all the patients had received follow-up either 
on an outpatient basis or by telephone interview. The living status of all included 
patients was confirmed.
Statistical Analysis
The t test was used for statistical analysis. Mathematical computation was con-
ducted using SPSS version 13.0 (SPSS Inc., Chicago, Illinois). Results are described as 
mean (SD). Significance level was set at P < 0.05. OAS was calculated from the first 
day of chemotherapy until death or last follow-up using the Kaplan-Meier method, 
and the log-rank test was used for comparison. DFS was calculated based on the date 
of documented detection of metastasis and/or local recurrence as the standard. The 
Cox regression model was used for multivariate comparisons (age, sex, and Cmax). 
Group t test was used to compare between-group differences. 
RESULTS
Analysis of Serum Concentration
A total of 98 patients were eligible for the study. However, 8 declined to enter the 
study, leaving 90 patients (58 men, 32 women; age range, 30–67 years). All patients 
underwent ≥3 courses of HD-MTX (6 or 8 g/m2) therapy, totaling 532 courses among 
all included patients. Overall, the serum MTX concentrations ranged widely at baseline 
(244.31–929.68 mol/L, Cmin and Cmax, respectively) and at 24 hours (0.73–28.24 mol/L, 
respectively), suggesting that the serum MTX concentrations varied significantly 
between different individuals and within the same individual at different time points. 
The present study also found that although the baseline serum MTX concentration in 
individual patients might have been higher than the mean (ie, >510.14 μmol/L), the 
concentration at 24 hours in the same patient was not necessarily higher than the 
mean (ie, >6.11 μmol/L). No correlation was found between high serum MTX con-
centration at baseline and high serum MTX concentration at 24 hours (r = 0.401).
Correlations Between MTX Concentration and Age, Sex, and Dosage
Mean serum MTX concentration was obtained from patients (90) who received 
≥3 courses of chemotherapy (total, 532). Age and sex were not associated with signifi-
Current Therapeutic Research
154
cant MTX concentrations; however, dosage was significantly associated with Cmax 
(Table I). At baseline, mean (SD) MTX concentrations were 418.60 (200.47) and 
595.83 (96.35) μmol/L at the 6- and 8-g/m2 doses, respectively (P = 0.02). At 24 hours, 
corresponding values were 5.15 (6.25) and 5.36 (4.29) μmol/L (P = NS).
Disease-Free Survival 
The 1- and 2-year DFS rates among included patients (N = 90) were 85% and 67%, 
respectively, with the follow-up ranging from 8 to 63 months; median, 25 months; and 
mean, 31.2 months. In the 2 subgroups (those with Cmax ≤500 μmol/L [n = 47] and 
those with Cmax >500 μmol/L [n = 43]) used to assess the relationship between Cmax 
and DFS, the median and mean DFSs in the first group were 27.6 and 21.0 months, 
respectively, whereas the median and mean DFSs in the second group were 50.0 and 
38.4 months (P = 0.040) (Figure 1). Among multivariate (age, sex, and Cmax) com-
parisons, the present study found that the Cmax was an independent prognostic factor 
(P = 0.049).
Overall Survival 
The 1- and 2-year OAS rates of the patients included in the analysis were 90% and 
76%, respectively. In the 2 groups combined, median and mean OASs were 33.0 and 
32.7 months in the first group (those with MTX Cmax ≤500 μmol/L [n = 47]) and 47.0 
and 45.2 months in the second group (those with MTX Cmax >500 μmol/L [n = 43]). 
Although the data found that the OAS rate in the second group was numerically 
higher than that of the first group, there was no statistical difference between the 
2 groups (Figure 2).
Table I.  Correlation between serum methotrexate (MTX) concentration and age, sex, 
and dose at baseline and 24 hours in Chinese adults undergoing chemotherapy 
for osteosarcoma. Data are mean (SD).
 Baseline 24 h
 Serum MTX  Serum MTX 
 Concentration,  Concentration, 
Variable μmol/L P μmol/L P
Age, y  0.09  0.40
  30–50 (n = 71) 493.59 (91.39)  4.47 (3.10)
  >50 (n = 19) 532.90 (104.47)  5.60 (4.29)
Sex  0.10  0.31
  Male (n = 58) 489.07 (88.42)  5.79 (3.91)
  Female (n = 32) 549.60 (104.88)  4.65 (4.30)
Dose, g/m2   0.02  0.84
  6 (n = 35) 418.60 (200.47)  5.15 (6.25)
  8 (n = 55)  595.83 (96.35)  5.36 (4.29)
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Adverse Reactions
Among the 90 patients who received ≥3 rounds of HD-MTX (6 or 8 g/m2) chemo-
therapy, in 122 of 532 cases, the serum MTX concentration was higher than the safety 
value (>10 μmol/L at 24 hours or >1 μmol/L at 48 hours). As shown in Table II, the 
patients whose MTX concentrations were higher than the safety value at 24 and/or 
48 hours had significantly higher incidences of some adverse reactions than those who 
had MTX concentrations below the safety value (ie, normal values). However, there 
were no significant differences between the subgroups with MTX concentrations 
above or below safety values with regard to the incidences of hepatic impairment and 
nausea and vomiting (Table II). In 13 of 122 cases, patients experienced severe ad-
verse reactions (bone marrow suppression [11.1%], dental ulcer [5.08%], and rash 
[4.5%]). In these cases, the MTX concentrations were higher than the safety values at 
both 24 and 48 hours, requiring additional CFR in these patients. These patients 
experienced complete recovery within 10 days of the discharge date.
DISCUSSION
MTX, an antifolate drug, has been widely used in the treatment of various tumors and 
immune suppression.10 It acts as a dihydrofolate reductase (DHFR) inhibitor that 
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Figure 1.  Analyses in patient subgroups (those with methotrexate [MTX] Cmax ≤500 μmol/L 
[n = 47] and those with Cmax >500 μmol/L [n = 43]) used to assess the rela-
tionship between Cmax and disease-free survival (DFS).
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Figure 2.  Analyses in patient subgroups (those with methotrexate [MTX] Cmax ≤500 μmol/L 
[n = 47] and those with Cmax >500 μmol/L [n = 43]) used to assess the rela-
tionship between Cmax and overall survival (OAS).
Table II.  Correlation between serum methotrexate (MTX) concentration and adverse 
reactions in Chinese adult patients undergoing chemotherapy for osteosarcoma. 
Data are no. (%) of patients.
 Serum MTX Serum MTX 
 Concentration Concentration Higher 
 Normal Values at Than Safety Values* at 
 24 and 48 h, μmol/L 24 and/or 48 h, μmol/L 
Adverse Reactions  (n = 410)  (n = 122) P
Impaired hepatic function  206 (50.2) 72 (59.0) 0.454
Nausea and vomiting 172 (42.0) 66 (54.1) 0.295
Depressed white blood cell count  60 (14.6) 54 (44.3) 0.002
Dental ulcer 16 (3.9) 28 (23.0) 0.005
Rash 10 (2.4) 22 (18.0) 0.008
Fever 0 16 (13.1) 0.001
*Safety values: ≤10 μmol/L at 24 hours and ≤1 μmol/L at 48 hours.7
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inhibits the metabolism of folic acid, DNA synthesis, and cell growth.10 MTX enters 
cells with the aid of a reduced folate carrier and generates polyglutamate methotrexate 
(MTXPG) by the catalysis of folylpolyglutamate synthase. Both MTX and MTXPG 
are competitors of dihydrofolic acid to bind with DHFR. MTXPG has a higher af-
finity to DHFR and dissociates slowly, making it a better inhibitor of DHFR than 
MTX.10 Eventually, the synthesis of DNA and RNA becomes restricted, causing the 
proliferating cancer cells to die. The sensitivity of tumor cells to MTX depends on 
intracellular MTX concentration. An appropriate concentration is crucial to 
achieve the best effect. Some studies have investigated a dose-response curve be-
tween HD-MTX and tumor cell cytotoxicity.11,12
The number of destroyed tumor cells has been found to exponentially increase 
when a double dose of chemotherapeutic agent is used.12 The international standard 
dose of MTX ranges from 8 g/m2 (adults) to 12 g/m2 (children).12 In this study, 
90 Chinese adult patients aged ≥30 years received HD-MTX (6 or 8 g/m2) chemo-
therapy. The analysis found significant differences between patients, possibly because 
of variations in MTX renal clearance. It also found variable differences in the same 
patient at different time points. Bacci et al13 conducted a study in 272 patients with 
OS who received HD-MTX (>10 g/m2) by IV infusion for 6 consecutive hours. The 
study found that complete historic MTX response rate in the group with a high mean 
Cmax (≥700 μmol/L) was significantly higher than that in the group that had a low mean 
Cmax (<700 μmol/L) (28% and 9.9%, respectively; P = 0.001), and that the 4-year 
OAS rate in the group with the higher mean Cmax was significantly higher (88% and 
58%; P < 0.007). Therefore, to obtain a serum Cmax ≥700 μmol/L, an MTX dose ad-
justment was recommended by those authors. Because the patients involved in the 
present study were adults aged ≥30 years and the MTX dosage was 6 or 8 g/m2, the 
serum MTX concentration resulted in a relatively lower mean (SD) Cmax (510.14 
[119.43] μmol/L) compared with the concentrations found by Bacci et al.13 Therefore, 
a higher MTX dosage was possibly used in these Chinese adult patients with OS in 
the effort to receive an enhanced therapeutic effect.
Much is still unknown regarding MTX pharmacokinetics, such as the exact meta-
bolic process, key factors that influence the metabolic process, and the effects, if any, 
of age and sex. In another study conducted by Bacci et al14 in 336 patients with OS 
of the extremities who were treated with 3 neoadjuvant protocols of chemotherapy, 
including HD-MTX (different doses for each protocol), MTX dose, not age or sex, 
was found to be a key factor influencing the mean serum Cmax. Patients treated with 
MTX doses of 8, 10, or 12 g/m2 had Cmax values of 578, 735, and 1114 μmol/L, 
respectively, demonstrating a significant difference between groups (P < 0.001). The 
results of the present study support the findings from the study by Bacci et al.14 In 
the present study, when MTX was administered at 6 and 8 g/m2, MTX concentra-
tions at baseline were 418.60 and 595.83 μmol/L, respectively, suggesting a signi- 
ficant difference in Cmax at different doses (P < 0.05). However, no significant dif- 
ference was found in MTX concentrations at 24 or 48 hours at different doses, 
suggesting that the dose did not affect the serum MTX concentrations at 24 or 
48 hours, probably due to the higher serum MTX concentration at baseline hav-
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ing produced an accelerated discharge, which is consistent with the findings in 
literature.15,16
Selecting 700 or 1000 μmol/L as the effective MTX Cmax has been controversial 
among researchers worldwide.17–21 In a study by Zelcer et al22 conducted in 48 pa-
tients with OS (adults and children) treated with HD-MTX, no correlation was found 
between DFS and Cmax or between a serum MTX concentration >1000 μmol/L and 
extended DFS. This study, however, was limited by its small sample size. In a separate 
study by Crews et al23 conducted in 140 children and adults with OS treated with 
HD-MTX, patients with a Cmax >1500 μmol/L appeared to have a poorer prognosis, 
in terms of 5-year survival, compared with those who had a Cmax of ≤1500 μmol/L. In 
the present study, 4 patients (0.04%) had a high Cmax (>700 μmol/L) at baseline. The 
mean Cmax was 505.83 μmol/L and the median Cmax was 499.56 μmol/L. DFS in the 
group with a Cmax of >500 μmol/L was significantly longer than that in the group 
with a Cmax of ≤500 μmol/L (P = 0.040). OAS in the group with the higher Cmax at 
baseline was numerically longer than that in the group with the lower Cmax but this 
difference was not statistically significant, likely because of the small population and 
brief follow-up. Further studies investigating these parameters are warranted.
Although HD-MTX therapy was associated with effectiveness survival, the inci-
dences of some adverse reactions were significantly higher than those associated with 
routine dose MTX (30–40 mg/m2) as well.24,25 The chemotherapeutic mortality rate 
was found to be ~6%. Nirenberg et al7 reported that irreversible damage would take 
place if serum MTX concentration was >10 μmol/L and >1 μmol/L at 24 and 48 hours, 
respectively. Impaired hepatic function, bone marrow depression, gastrointestinal 
mucositis, and ulcer were all common adverse reactions experienced, probably due to 
the short cell cycle and rapid proliferation associated with MTX use, resulting in cell 
damage.19 Therefore, it was necessary to minimize these reactions in chemotherapy 
with HD-MTX in the present study, and CFR was crucial in decreasing the incidence 
of adverse reactions associated with HD-MTX use. Routine CFR was administered 
12 hours after HD-MTX administration in many cases. The dosage of CFR accounted 
for 3% to 5% of MTX. If the serum MTX concentrations at 24, 48, and 72 hours were 
higher than the safety values, CFR would need to be administered more frequently 
based on the CFR dosing schedule. At the same time, water and basic electrolytes 
would be required to obtain 3000 mL of urinary output each day and a urinary pH 
>7.0. In addition, oral allopurinol administration was necessary to prevent the inhibi-
tion of MTX and its metabolite crystal in the nephric tubule due to severe renal func-
tion damage. Among the patients who received HD-MTX (6 or 8 g/m2) in this study, 
122 of 532 cases had serum MTX concentrations that were higher than the safety 
values at 24 hours (10 μmol/L) and/or 48 hours (1 μmol/L). Compared with the pa-
tients whose serum MTX concentrations were lower than the safety values, patients 
with serum MTX concentrations higher than the safety values were more likely to 
experience bone marrow suppression, dental ulcer, rash, and fever, but the incidences 
of hepatic impairment and gastrointestinal reaction were not significantly different be-
tween the 2 subgroups. In 13 of 122 cases in which MTX concentrations were higher 
than safety values, at both 24 and 48 hours, severe adverse reactions (bone marrow sup-
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pression [11.1%], dental ulcer [5.1%], and rash [4.5%]) occurred. CFR administra- 
tion was particularly important in these patients, and they experienced complete recovery 
within 10 days of the discharge date. In addition to increasing CFR administration 
frequency and dosage, other measures undertaken were elevating the WBC and platelet 
counts via granulocyte colony-stimulating factor and interleukin-11, proper blood com-
ponent transfusion, oral care with CFR, confinement in a sterile room, and antibiotic 
administration. Patients with mild or moderate adverse reactions usually recovered 
within 3 to 5 days. 
Limitations
The present study used a retrospective analysis of serum MTX concentrations at 
different dosages. It provides information on relationships between serum MTX con-
centration and prognosis and tolerability in these Chinese adult patients with OS. 
Because this study was not blinded or randomized, the findings might have been 
subject to bias. A prospective study is currently under way at the Affiliated People’s 
6th Hospital.
CONCLUSIONS
The present study found that serum MTX concentrations measured at different time 
points were variable within and between these Chinese adult patients. Adverse reac-
tions occurred at a higher frequency in patients whose serum MTX concentrations at 
24 and 48 hours were higher than the safety values (10 μmol/L and 1 μmol/L, respec-
tively). The dosage, but not sex and age, appeared to influence MTX Cmax, and Cmax 
was significantly related to DFS but not OAS in this study. 
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